WO2002083110A3 - Modele animal pour l'evaluation d'analgesiques - Google Patents
Modele animal pour l'evaluation d'analgesiques Download PDFInfo
- Publication number
- WO2002083110A3 WO2002083110A3 PCT/IB2002/001140 IB0201140W WO02083110A3 WO 2002083110 A3 WO2002083110 A3 WO 2002083110A3 IB 0201140 W IB0201140 W IB 0201140W WO 02083110 A3 WO02083110 A3 WO 02083110A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- analgesics
- animal model
- evaluating
- nsaid
- trauma
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02727818A EP1379226A2 (fr) | 2001-04-10 | 2002-04-10 | Modele animal pour l'evaluation d'analgesiques |
AU2002258013A AU2002258013A1 (en) | 2001-04-10 | 2002-04-10 | Animal model for evaluating analgesics |
PCT/IB2002/001140 WO2002083110A2 (fr) | 2001-04-10 | 2002-04-10 | Modele animal pour l'evaluation d'analgesiques |
CA002455274A CA2455274A1 (fr) | 2001-04-10 | 2002-04-10 | Modele animal pour l'evaluation d'analgesiques |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28249701P | 2001-04-10 | 2001-04-10 | |
US60/282,497 | 2001-04-10 | ||
PCT/IB2002/001140 WO2002083110A2 (fr) | 2001-04-10 | 2002-04-10 | Modele animal pour l'evaluation d'analgesiques |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002083110A2 WO2002083110A2 (fr) | 2002-10-24 |
WO2002083110A3 true WO2002083110A3 (fr) | 2003-10-16 |
Family
ID=26318637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2002/001140 WO2002083110A2 (fr) | 2001-04-10 | 2002-04-10 | Modele animal pour l'evaluation d'analgesiques |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2002083110A2 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY28583A1 (es) * | 2003-10-30 | 2005-05-31 | Roche Consumer Health Ag | Forma de presentación del naproxeno sodico |
-
2002
- 2002-04-10 WO PCT/IB2002/001140 patent/WO2002083110A2/fr not_active Application Discontinuation
Non-Patent Citations (7)
Title |
---|
DRESSMAN J B ET AL: "Gastrointestinal parameters that influence oral medications.", JOURNAL OF PHARMACEUTICAL SCIENCES. UNITED STATES SEP 1993, vol. 82, no. 9, September 1993 (1993-09-01), pages 857 - 872, XP002247244, ISSN: 0022-3549 * |
HARUTA SHUNJI ET AL: "Absorption behavior of orally administered drugs in rats treated with propantheline.", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 87, no. 9, 1998, pages 1081 - 1085, XP002247242, ISSN: 0022-3549 * |
JAMALI FAKHREDDIN ET AL: "Pain-mediated altered absorption and metabolism of ibuprofen: An explanation for decreased serum enantiomer concentration after dental surgery.", BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, vol. 47, no. 4, April 1999 (1999-04-01), pages 391 - 396, XP002247241, ISSN: 0306-5251 * |
JOEL SIMON P ET AL: "Pharmacological attempts to improve the bioavailability of oral etoposide.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 37, no. 1-2, 1995, pages 125 - 133, XP002247243, ISSN: 0344-5704 * |
See also references of EP1379226A2 * |
WOJCICKI J ET AL: "EFFECT OF PAPAVERINE AND ATROPINE ON PHARMACOKINETICS OF PARACETAMOL ADMINISTERED ORALLY", POLISH JOURNAL OF PHARMACOLOGY AND PHARMACY, POLISH ACADEMY OF SCIENCES INSTITUTE OF, PL, vol. 31, no. 3, 1997, pages 239 - 243, XP000974559, ISSN: 0301-0244 * |
YAMAKITA H ET AL: "IN VITRO/IN VIVO EVALUATION OF TWO SERIES OF TA-5707F CONTROLLED RELEASE MATRIX TABLETS PREPARED WITHHYDROXYPROPYL METHYL CELLULOSE DERIVATIVES WITH ENTERO-SOLUBLE OR GEL-FORMATION PROPERTIES", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 18, no. 10, 1 October 1995 (1995-10-01), pages 1409 - 1416, XP000537682, ISSN: 0918-6158 * |
Also Published As
Publication number | Publication date |
---|---|
WO2002083110A2 (fr) | 2002-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003096990A3 (fr) | Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale | |
AU2002318759A1 (en) | Remedies for diseases with bone mass loss having EP4 agonists as the active ingredient | |
WO2005000161A3 (fr) | Procedes et dispositifs d'occlusion d'une lumiere corporelle et/ou d'administration d'agents therapeutiques | |
WO2004006858A3 (fr) | Composes, compositions et methodes d'utilisation de ces derniers | |
MX255941B (es) | Derivado de isoxazolina y herbicida que lo contiene como ingrediente activo. | |
NO20040564L (no) | Karboksylsyrederivatforbindelser og legemidler omfattende disse forbindelser som den aktive bestanddel | |
WO2002080969A1 (fr) | Remedes pour des maladies liees a l'arthrite chronique du nourrisson | |
WO2004064595A3 (fr) | Produits de synthese multivalents pour applications therapeutiques et diagnostiques | |
WO2005009381A3 (fr) | Preparation a liberation immediate de compositions pharmaceutiques labiles en milieu acide | |
WO2002096363A3 (fr) | Methode de traitement de maladies fibreuses ou d'autres indications | |
AU2002347910A1 (en) | Methods and compositions for targeting proteins across the blood brain barrier | |
IL172423A0 (en) | Novel formulations for opioid -based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | |
DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
WO2004091591A3 (fr) | Composition nutritionnelle ou therapeutique contenant le compose oleurofeine ou l'un de ses derives | |
WO2004041158A3 (fr) | Compositions de rifalazil et regimes therapeutiques | |
WO2004073615A3 (fr) | Composes de deazaflavine et leurs methodes d'utilisation | |
ITRM20030363A1 (it) | Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse. | |
WO2002034240A3 (fr) | Formulations a liberation retardee et prolongee et procede d'utilisation | |
WO2001051072A3 (fr) | Agent antiparasitaire | |
WO2002053149A3 (fr) | Medicaments contenant une polyamine en tant que principe actif | |
MXPA02012857A (es) | Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado. | |
WO2002060533A3 (fr) | Compositions medicamenteuses a faibles effets secondaires | |
WO2003007876A3 (fr) | Conjugues acide amine-acide gras normal et utilisations therapeutiques | |
WO2002083110A3 (fr) | Modele animal pour l'evaluation d'analgesiques | |
HK1065305A1 (en) | Substituted 4-aminocyclohexanol derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2455274 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002727818 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002727818 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWR | Wipo information: refused in national office |
Ref document number: 2002727818 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002727818 Country of ref document: EP |